Cargando…
Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs
Schizophrenia is a chronic psychiatric disorder which substantially impairs patients’ quality of life. Despite the extensive research in this field, the pathophysiology and etiology of schizophrenia remain unknown. Different neurotransmitter systems and functional networks have been found to be affe...
Autores principales: | Muguruza, Carolina, Meana, J. Javier, Callado, Luis F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873505/ https://www.ncbi.nlm.nih.gov/pubmed/27242534 http://dx.doi.org/10.3389/fphar.2016.00130 |
Ejemplares similares
-
Group 1 Metabotropic Glutamate Receptor Function and Its Regulation of Learning and Memory in the Aging Brain
por: Ménard, Caroline, et al.
Publicado: (2012) -
Group I Metabotropic Glutamate Receptor-Mediated Gene Transcription and Implications for Synaptic Plasticity and Diseases
por: Wang, Hansen, et al.
Publicado: (2012) -
Differential brain ADRA2A and ADRA2C gene expression and epigenetic regulation in schizophrenia. Effect of antipsychotic drug treatment
por: Brocos-Mosquera, Iria, et al.
Publicado: (2021) -
Targeting the Type 5 Metabotropic Glutamate Receptor: A Potential Therapeutic Strategy for Neurodegenerative Diseases?
por: Budgett, Rebecca F., et al.
Publicado: (2022) -
The Metabotropic Purinergic P2Y Receptor Family as Novel Drug Target in Epilepsy
por: Alves, Mariana, et al.
Publicado: (2018)